Lung Transplant Rejection - Pipeline Review, H1 2017

  • ID: 4267352
  • Report
  • 65 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Dompe Farmaceutici SpA
  • Kamada Ltd
  • Novartis AG
  • Quark Pharmaceuticals Inc
  • MORE
Lung Transplant Rejection - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Lung Transplant Rejection - Pipeline Review, H1 2017, provides an overview of the Lung Transplant Rejection (Immunology) pipeline landscape.

Lung transplantation is the therapy used in various lung diseases. Lung transplant replaces an injured or diseased lung with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted lung as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously which prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Lung Transplant Rejection - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Lung Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lung Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Lung Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 4 and 1 respectively.

Lung Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Lung Transplant Rejection (Immunology).
- The pipeline guide reviews pipeline therapeutics for Lung Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Lung Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Lung Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Lung Transplant Rejection (Immunology)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Lung Transplant Rejection (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Lung Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Dompe Farmaceutici SpA
  • Kamada Ltd
  • Novartis AG
  • Quark Pharmaceuticals Inc
  • MORE
Introduction

Lung Transplant Rejection - Overview

Lung Transplant Rejection - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Lung Transplant Rejection - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Lung Transplant Rejection - Companies Involved in Therapeutics Development

Dompe Farmaceutici SpA

Kamada Ltd

Novartis AG

Quark Pharmaceuticals Inc

Lung Transplant Rejection - Drug Profiles

alpha-1 proteinase inhibitor (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

everolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FX-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QPI-1024 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QPLI-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-554 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

reparixin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solnatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tiprelestat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lung Transplant Rejection - Dormant Projects

Lung Transplant Rejection - Product Development Milestones

Featured News & Press Releases

Apr 06, 2016: Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection

Dec 09, 2015: Quark announces issue of U.S. patent for novel treatment of lung transplantation associated injury

Jun 22, 2015: Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection

Mar 12, 2015: Elafin combined with cyclosporine promises to overcome limitations of cyclosporine for preventing irreversible damage to transplanted organs

Apr 17, 2013: APEPTICO initiates phase II clinical trial with AP301 in patients with primary graft dysfunction following lung transplantation

Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program

Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Lung Transplant Rejection, H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Lung Transplant Rejection - Pipeline by Apeptico Forschung und Entwicklung GmbH, H1

Lung Transplant Rejection - Pipeline by Dompe Farmaceutici SpA, H1

Lung Transplant Rejection - Pipeline by Kamada Ltd, H1

Lung Transplant Rejection - Pipeline by Novartis AG, H1

Lung Transplant Rejection - Pipeline by Quark Pharmaceuticals Inc, H1

Lung Transplant Rejection - Dormant Projects, H1

List of Figures:

Number of Products under Development for Lung Transplant Rejection, H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Dompe Farmaceutici SpA
  • Kamada Ltd
  • Novartis AG
  • Quark Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll